Uveitis Market: Global Industry Analysis and Forecast to 2015 to 2021

  • To Be Published : Dec-2016 |
  • Status : Work in progress |
  • Format :

Uveitis is the inflammation of middle layer of eye commonly known as uvea. Uvea consists of pigmented and non pigmented tissues which are present in the middle layer of the eye. The uvea is also known as uveal tract. The uveal tract is important for eye nutrition and for reduction of glare of light which enters into the eye through absorption of the light. In addition, uvea also helps in aqueous humour generation and eye lens protection. The uvea consists of choroid, iris and ciliary bodies. Choroids exist between the retina and the white part of the eye. Choroid helps in blood flow to the deep layer of the retina. Iritis, an inflammation of iris, is the most common form of uveitis. Anterior uveitis, posterior uveitis, intermediate uveitis and pan uveitis are some of the types of uveitis. Anterior uveitis involves inflammation of front part of eye. It is the most common type of uveitis and affects young and middle age people. Posterior uveitis includes the choroid, a layer of connective tissues and blood vessel in the middle part of the eye. Posterior uveitis results into inflammation of back part of uvea. Blurred vision, eye pain, redness of eye, dark floating spot in vision and sensitivity to light are some of the symptoms for the uveitis.

Injuries, infections and autoimmune disorders are some of the causes for uveitis. Uveitis is also caused due to infection from various diseases such as brucellosis, lyme disease, tuberculosis, toxocariasis and syphilis. In addition, drug interaction also causes uveitis. Uveitis treatment is basically symptom specific with the help of steroid and non-steroidal anti inflammatory drugs. Uveitis drugs are present in various forms such as eye drops and oral medication. Ophthalmic steroids with anti-infective, corticosteroids, antimetabolites, glucocorticoid steroid and antirheumatics are some of the medication classes used to treat uveitis. 

North America is dominating the global uveitis market due to early approval of pipeline drugs compare to other regions. The Asia Pacific and the European countries are also expected to show high growth rate due to rising number of patients suffering from autoimmune disorders and other eye related diseases.

In recent time there is increases use of uveitis drugs due to increasing prevalence of eye disorders. Increasing number of biologics and introduction of new routes for administration of uveitis drugs and increase in R&D initiatives are some of the key factors driving the growth of the global uveitis market. In addition, rising aging population and increasing number of lifestyle associated diseases are also fuelling the growth of the global uveitis market. However, lack of awareness and high cost of medication are some of the factors restraining the growth of the global uveitis market. 

Adverse effect of medication such as irritation and watery eyes could be a challenge for the growth of the global uveitis market. Innovative pipeline drugs would be an opportunity for the growth of the global uveitis market. Some of the major companies operating in the global uveitis market are Alcon Laboratories Inc., Allergan Inc., Bausch & Lomb Inc., Novartis AG, Santen Pharmaceutical Co. Ltd. and AbbVie, Inc.

Key geographies evaluated in this report are:

  • North America
    • U.S
    • Canada
  • Europe
    • France, Germany, Italy, Spain, and the UK
    • Eastern Europe
    • CIS
  • APAC
    • China
    • India
    • Japan
    • Australia
    • Others
  • Latin America
    • Argentina
    • Brazil
    • Others

Key features of this report

  • Drivers, restraints, and challenges shaping the Uveitis market dynamics
  • Latest innovations and key events in the industry
  • Analysis of business strategies of the top players
  • Uveitis market estimates and forecasts(2015 -2021)
Back To Top